This report was first published by Endpoints News. To see the original version, click here
The biopharma industry is looking for creative ways to cushion the effect of the Trump administration’s “most favored nation” deals on US pricing.
Two lawyers who work with biopharma companies told Endpoints News that they’ve had an uptick in inquiries on whether amending licensing contracts could be a way to do so.
您已阅读11%（406字），剩余89%（3218字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。